Get the Stockscreener App
1.125
1.80%
0.015
Ocugen Inc stock is traded at $1.125, with a volume of 1.54M.
It is up +1.80% in the last 24 hours and down -28.03% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.11
Open:
$1.11
24h Volume:
1.54M
Relative Volume:
0.33
Market Cap:
$351.36M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-4.1667
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-5.04%
1M Performance:
-28.03%
6M Performance:
+36.14%
1Y Performance:
+25.43%
1-Day Range:
$1.09
$1.15
1-Week Range:
$1.09
$1.271
52-Week Range:
$0.515
$1.90
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.125 | 346.68M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.64 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.68 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.20 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.13 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.30 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Will Ocugen Inc. (2H51) stock outperform energy sector in 20252025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Is Ocugen Inc. stock a defensive play in 20252025 Dividend Review & Real-Time Market Trend Scan - newser.com
Why retail investors favor Ocugen Inc. stockWeekly Trend Summary & AI Forecasted Stock Moves - newser.com
How Ocugen Inc. (2H51) stock trades after rate cuts2025 Price Action Summary & Verified Technical Signals - newser.com
Ocugen CEO to Present at NobleCon21-Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference - The Manila Times
Ocugen CEO Dr. Shankar Musunuri to Present at NobleCon21 Conference on Advancements in Gene Therapies for Blindness Diseases - Quiver Quantitative
Ocugen (NASDAQ: OCGN) CEO to Present on Three BLAs in Three Years at NobleCon21 - Stock Titan
How Ocugen Inc. (2H51) stock compares with tech leaders2025 Price Momentum & Scalable Portfolio Growth Ideas - newser.com
Why Ocugen Inc. (2H51) stock could outperform next yearPortfolio Value Summary & AI Optimized Trading Strategy Guides - newser.com
Is Ocugen Inc. (2H51) stock resilient in recession scenarios - newser.com
Is Ocugen Inc. showing signs of accumulationSwing Trade & Weekly Top Performers Watchlists - newser.com
How Ocugen Inc. stock reacts to job market data2025 Momentum Check & Low Drawdown Trading Strategies - newser.com
Can Ocugen Inc. stock continue upward trendJuly 2025 Selloffs & Real-Time Volume Analysis - newser.com
Analyzing net buyer seller activity in Ocugen Inc.2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
What hedge fund moves indicate for Ocugen Inc. (2H51) stockRisk Management & Consistent Profit Alerts - newser.com
How Ocugen Inc. stock performs in high volatility marketsWeekly Trend Summary & Weekly High Return Stock Opportunities - newser.com
Can Ocugen Inc. (2H51) stock attract ESG investments2025 Volatility Report & Fast Entry High Yield Tips - newser.com
Gene Therapy for Ocular Rare Disease Market to Exhibit Phenomenal Growth During the Forecast Period (2025–2034) Due to Expanding Pipeline and Clinical Trial Activities | DelveInsight - GlobeNewswire Inc.
Is Ocugen Inc. stock resilient to inflationTrade Exit Report & Safe Entry Zone Identification - newser.com
Will Ocugen Inc. stock maintain dividend yieldAnalyst Downgrade & Risk Managed Trade Strategies - newser.com
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):